TNFRSF18 and neoplasm: The current study was executed with the hypothesis that Listeria-based immunotherapy will generate an antigen-specific immune response with a decreased population of suppressive cells, and stimulation with anti-GITR agonist mAb will further enhance the antigen-specific immune response and may subsequently lead to a profound anti-tumor effect.